Soft multifocal lenses show promise as a management tool for accommodation and vergence disorders in patients without presbyopia.
The VEGA-3 Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia is also enrolling patients. Top-line results are expected in the first half of 2025. The ...
A live audio webcast of the Piper Sandler Healthcare Conference fireside chat can be accessed here and on the LENZ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback